Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. (Q33415723)

26 July 2017

Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. (English)

1 reference

26 July 2017

1 reference

6

Eike C Buss

1 reference

26 July 2017

Gernot Polier

1

1 reference

26 July 2017

Marco Giaisi

2

1 reference

26 July 2017

Rebecca Köhler

3

1 reference

26 July 2017

Wolfgang W Müller

4

1 reference

26 July 2017

Christoph Lutz

5

1 reference

26 July 2017

Peter H Krammer

7

1 reference

26 July 2017

Min Li-Weber

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

13 June 2014

1 reference

International Journal of Cancer

26 July 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 July 2017

136

1 reference

26 July 2017

3

1 reference

26 July 2017

688-698

1 reference

BH3-only proteins and their roles in programmed cell death

26 July 2017

1 reference

BCL-2 family antagonists for cancer therapy

21 January 2018

1 reference

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins

21 January 2018

1 reference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis

21 January 2018

1 reference

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

21 January 2018

1 reference

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

21 January 2018

1 reference

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

21 January 2018

1 reference

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

21 January 2018

1 reference

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation

21 January 2018

1 reference

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

21 January 2018

1 reference

Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation

21 January 2018

1 reference

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib

21 January 2018

1 reference

Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression

21 January 2018

1 reference

Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy

21 January 2018

1 reference

Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.

21 January 2018

1 reference

Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis

21 January 2018

1 reference

Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts

21 January 2018

1 reference

Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis

21 January 2018

1 reference

Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2.

21 January 2018

1 reference

The anticancer activities of wogonin in murine sarcoma S180 both in vitro and in vivo

21 January 2018

1 reference

A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer

21 January 2018

1 reference

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer

21 January 2018

1 reference

21 January 2018

1 reference

Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases

21 January 2018

1 reference

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

21 January 2018

1 reference

BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation

21 January 2018

1 reference

Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells

21 January 2018

1 reference

Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen

21 January 2018

1 reference

Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix

21 January 2018

1 reference

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

21 January 2018

1 reference

Toxicological studies of wogonin in experimental animals

21 January 2018

1 reference

Cell death in hematological tumors

21 January 2018

1 reference

Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas

21 January 2018

1 reference

XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells

21 January 2018

1 reference

IAP proteins: blocking the road to death's door

21 January 2018

1 reference

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

Selective control of gene expression by CDK9 in human cells

21 January 2018

1 reference

CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.

21 January 2018

1 reference

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

21 January 2018

1 reference

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

21 January 2018

1 reference

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

21 January 2018

1 reference

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling

21 January 2018

1 reference

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

21 January 2018

1 reference

A human cell line from a pleural effusion derived from a breast carcinoma

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1093/JNCI/51.5.1409

Identifiers

DOI

10.1002/IJC.29009

1 reference

26 July 2017

1 reference